Download video

Lower-risk MDS in 2021: luspatercept, imetelstat & roxadustat

1.2K views

VJHemOnc – Video Journal of Hematology & HemOnc

3 years ago

Lower-risk MDS in 2021: luspatercept, imetelstat & roxadustat

Lower-risk MDS in 2021: luspatercept, imetelstat & roxadustat

Lower-risk MDS in 2021: luspatercept, imetelstat \& roxadustat
4:35
Lower-risk MDS in 2021: luspatercept, imetelstat \& roxadustat
by VJHemOnc – Video Journal of Hematology \& HemOnc
Imetelstat in heavily-transfused lower-risk R\/R MDS
2:00
Imetelstat in heavily-transfused lower-risk R\/R MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
The promise of luspatercept for the treatment of lower-risk MDS
0:56
The promise of luspatercept for the treatment of lower-risk MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
COMMANDS trial: luspatercept vs epoetin alfa in lower-risk MDS
1:06
COMMANDS trial: luspatercept vs epoetin alfa in lower-risk MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
Overall survival of patients following treatment with luspatercept in the MEDALIST trial
1:31
Overall survival of patients following treatment with luspatercept in the MEDALIST trial
by VJHemOnc – Video Journal of Hematology \& HemOnc
IMerge subgroup study: imetelstat in patients with LR-MDS previously exposed to ESAs
1:25
IMerge subgroup study: imetelstat in patients with LR-MDS previously exposed to ESAs
by VJHemOnc – Video Journal of Hematology \& HemOnc
Improving the treatment of low-risk MDS: luspatercept, treatment sequencing \& disease classification
2:12
Improving the treatment of low-risk MDS: luspatercept, treatment sequencing \& disease classification
by VJHemOnc – Video Journal of Hematology \& HemOnc
Imetelstat efficacy is independent of molecular subtypes in R\/R LR-MDS
3:50
Imetelstat efficacy is independent of molecular subtypes in R\/R LR-MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
Luspatercept for the treatment of patients with lower-risk MDS and ESA failure
1:15
Luspatercept for the treatment of patients with lower-risk MDS and ESA failure
by VJHemOnc – Video Journal of Hematology \& HemOnc
Luspatercept reduces transfusion burden in MDS-related anemia: MEDALIST results
6:32
Luspatercept reduces transfusion burden in MDS-related anemia: MEDALIST results
by VJHemOnc – Video Journal of Hematology \& HemOnc
How Is Luspatercept Being Used in Lower-Risk MDS Management?
2:58
How Is Luspatercept Being Used in Lower-Risk MDS Management?
by Blood Cancers Today
MEDALIST: luspatercept and erythropoiesis biomarkers in MDS
2:30
MEDALIST: luspatercept and erythropoiesis biomarkers in MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
Recent advances in the treatment of LR-MDS: COMMANDS and IMerge trial data
4:32
Recent advances in the treatment of LR-MDS: COMMANDS and IMerge trial data
by VJHemOnc – Video Journal of Hematology \& HemOnc
IMerge update: continuous transfusion independence \& disease modification with imetelstat in LR-MDS
1:44
IMerge update: continuous transfusion independence \& disease modification with imetelstat in LR-MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
Imetelstat for transfusion-dependent R\/R MDS
2:19
Imetelstat for transfusion-dependent R\/R MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
Phase III MEDALIST Trial of Luspatercept for MDS
7:14
Phase III MEDALIST Trial of Luspatercept for MDS
by OncLive
Prolonged \& continuous transfusion independence after imetelstat treatment in the IMerge trial
3:12
Prolonged \& continuous transfusion independence after imetelstat treatment in the IMerge trial
by VJHemOnc – Video Journal of Hematology \& HemOnc
State-of-the-art treatment regimens for LR-MDS
7:05
State-of-the-art treatment regimens for LR-MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
Treatment of anemia in LR-MDS: luspatercept and imetelstat
3:41
Treatment of anemia in LR-MDS: luspatercept and imetelstat
by VJHemOnc – Video Journal of Hematology \& HemOnc
IMerge results: efficacy and disease-modifying activity of imetelstat in LR-MDS after ESA failure
2:40
IMerge results: efficacy and disease-modifying activity of imetelstat in LR-MDS after ESA failure
by VJHemOnc – Video Journal of Hematology \& HemOnc